Blog

 

Rosetta Genomics To Market MicroRNA-based Diagnostics

Rosetta Genomics has entered into a co-marketing agreement for its miRview® mets2 assay for the identification of the tumor of origin in Cancers of Unknown or Uncertain Primary (“CUP”) with Precision Therapeutics Inc. Under the terms of the agreement, Rosetta Genomics granted Precision Therapeutics the co-exclusive right, along with Rosetta...
Read more

Pluristem Applies for Orphan Drug Status for Aplastic Anemia

Pluristem has filed documents requesting that the U.S. Food and Drug Administration (FDA) grant orphan drug status to its PLacental eXpanded (PLX) cells for the treatment of aplastic anemia. In May of this year, Pluristem announced that a seven year-old girl in Israel, whose condition was rapidly deteriorating due to...
Read more

Software Detects Snoring

For the 80 percent of people who are in denial over their nighttime chainsaw snoring, Snoring U has an app to show how bad the situation is. Snoring U is a $5 application you can download from the Internet for your smartphone or tablet. The app won’t only monitor your...
Read more

IP Rights for Employee Inventors

The US Supreme Court ruling in Dr. Bayer v Plurality Ltd allowed the appeal of an employee who signed an agreement that provided for the employee’s waiver of his right to remuneration for service inventions, holding that notwithstanding such express contractual waiver, the employee is entitled to submit a claim...
Read more

BrainStorm Success With ALS Patient

Israeli Channel 2 TV interviewed a patient suffering from Myasthenia Gravis (MG) and recently diagnosed with ALS. The patient reported that he has experienced visible improvement in his speech, walking, balance, posture, muscle strength, appetite, digestion, and weight gain following compassionate treatment with BrainStorm’s NurOwn cell therapy. “Due to the...
Read more